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Abstract
Introduction: Health care utilization databases have been increasingly used for studies of rheumatoid arthritis (RA).
However, the accuracy of RA diagnoses in these data has been inconsistent.
Methods: Using medical records and a standardized abstraction form, we examined the positive predictive value
(PPV) of several algorithms to define RA diagnosis using claims data: A) at least two visits coded for RA (ICD-9, 714);
B) at least three visits coded for RA; and C) at least two visits to a rheumatologist for RA. We also calculated the
PPVs for the subgroups identified by these algorithms combined with pharmacy claims data for at least one
disease-modifying anti-rheumatic drug (DMARD) prescription.
Results: We invited 9,482 Medicare beneficiaries with pharmacy benefits in Pennsylvania to participate; 2%
responded and consented for review of their medical records. There was no difference in characteristics between
respondents and non-respondents. Using ‘RA diagnosis per rheumatologists’ as the gold standard, the PPVs were
55.7% for at least two claims coded for RA, 65.5% for at least three claims for RA, and 66.7% for at least two
rheumatology claims for RA. The PPVs of these algorithms in patients with at least one DMARD prescription
increased to 86.2%-88.9%. When fulfillment of 4 or more of the ACR RA criteria was used as the gold standard, the
PPVs of the algorithms combined with at least one DMARD prescriptions were 55.6%-60.7%.
Conclusions: To accurately identify RA patients in health care utilization databases, algorithms that include both
diagnosis codes and DMARD prescriptions are recommended.
Introduction
Large automated databases such as health care utiliza-
tion and medical record databases have been widely
used as data sources for epidemiologic studies [1].
Validity and completeness of prescription drug data in
health care utilization databases with the prescription
drug plan have been checked several times and reported
as being of high quality [2], but the accuracy of specific
disease data such as diagnosis of rheumatoid arthritis
(RA) in health care utilization data has been somewhat
questionable.
Several studies previously examined the accuracy of
RA diagnoses in various data sources and reported
inconsistent results [3-8].Ap r e v i o u ss t u d ye x a m i n e d
the accuracy of computerized database diagnoses of RA
among the Olmsted County residents in Minnesota on
the basis of chart review and found a sensitivity of 89%,
a specificity of 74%, and a positive predictive value
(PPV) of 57% by using the American College of Rheu-
matology (ACR) RA criteria as the gold standard [3].
The PPV of the RA diagnosis codes alone was only 66%
compared with the gold standard definition of RA diag-
nosis by a rheumatologist on two separate visits in a
study using the Minneapolis Veterans Affairs adminis-
trative data [7]. A Danish national register-based study
showed that 59% of the subjects identified by the algo-
rithm using only discharge diagnosis codes had a clinical
diagnosis of RA and that 46% of those met the ACR cri-
teria for RA [8].
However, the sensitivity and PPV were over 90% for the
chart documentation of RA diagnosis in a study of Medi-
care diagnosis claims for RA from several rheumatology
practices [4]. The PPV of the RA diagnosis codes from
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recipients was 86% for the chart documentation of RA
diagnosis [5]. Another administrative data-based algorithm
with at least two physician visit claims for RA (with at
least 30 days between the visits) had a PPV of 92% for RA
based on a patient self-report questionnaire [6].
In this study, we developed several diagnosis code-
based algorithms with and without a link to pharmacy
claims for disease-modifying antirheumatic drugs
(DMARDs) to define the outpatient diagnosis of RA in a
health care utilization database and compared the validity
of these algorithms to various gold standard definitions.
Materials and methods
Data source
We studied participants in the Pennsylvania Assistance
Contract for the Elderly (PACE) program, established in
1984 to assist Pennsylvania residents who are 65 years
or older, who are of low to moderate income, and who
may suffer financial hardship in paying for their medica-
tion. The PACE program provides pharmacy benefits for
all drugs, including DMARDs and biologic therapy, for
qualifying residents who are 65 or older. All PACE par-
ticipants receive Medicare benefits. Data use agreements
w e r ei np l a c ew i t hM e d i c a r ea n dt h eP A C Ep r o g r a m
that supplied information for the study database. This
work was approved by Brigham and Women’s Hospital’s
Institutional Review Board.
Study procedures
Three different algorithms were used to identify patients
with RA by using the Medicare claim data from 1994 to
2004: (a) beneficiaries with at least two claims associated
with RA (International Classification of Diseases, 9th
Revision, Clinical Modification [ICD-9 CM] code 714),
(b) beneficiaries with at least three claims associated with
RA, and (c) beneficiaries with at least two RA claims that
were from a rheumatologist and that were separated by
at least 7 days. All inpatient, outpatient, and procedure
claims such as laboratory or radiologic tests were
included. We identified rheumatologists with a Medicare
provider specialty code in the database and verified them
with the ACR membership directory. A subgroup of
patients who filled at least one prescription for DMARDs
over a period of 1 year after the RA diagnosis was then
identified by using the data from both pharmacy benefit
program and claim data for infusions. To compare base-
line characteristics of the study subjects, we selected a
group of beneficiaries who never had any claims for RA.
After identifying subjects by each of the algorithms,
we attempted to obtain consent to review their medical
record. First, the PACE program mailed a letter to the
groups of subjects identified by our algorithms to inform
them that they would be contacted by our research
group. A letter that provided details about the study was
then sent to the subjects in each of the groups and
asked whether they would consent to have the study
researchers review their medical records from their phy-
sicians, including doctors who treated them for arthritis.
Subjects who agreed to participate in the study signed a
consent and authorization form for release of medical
records. Additionally, subjects were asked to complete a
physician information form to identify their primary
physicians as well as specialists and their contact infor-
mation. We then attempted to obtain copies of medical
records.
Once we received the medical records, all personal
identifiers were removed from the records for protection
of patients’ privacy. Medical records were reviewed inde-
pendently by several rheumatologists at Brigham and
Women’s Hospital. To minimize inter-reviewer variation
in data abstraction, a structured data abstraction form
was developed and pilot-tested with the principal investi-
gator (DHS). The form included items such as the seven
ACR 1987 classification criteria for RA, disease onset,
other rheumatologic diagnoses, medications, and labora-
tory data. On the basis of these data, the reviewers
assessed whether a patient met the gold standard defini-
tions of RA: (a) diagnosis of RA by a rheumatologist and
(b) fulfillment of the ACR criteria for RA. Any indication
in the medical record that the diagnosing rheumatolo-
gists thought that the patient had RA at that time was
counted as having ‘RA diagnosis per rheumatologists’.
When the patients were not seen by rheumatologists,
‘RA diagnosis per rheumatologists’ was made by the
reviewers on the basis of the data from their medical
records. When the diagnosis of RA was neither docu-
mented nor clear in their medical records, the patients
were considered non-RA. Areas of disagreement or
uncertainty were resolved by consensus. The study per-
iod for data collection from medical records lasted from
2004 to 2008.
Statistical analyses
We calculated PPV as the percentage of the patients who
met the gold standard definitions among those identified
by the algorithms. We also examined the PPVs of these
algorithms combined with at least one prescription fill
for a DMARD (Table 1). Ninety-five percent confidence
intervals (CIs) of the PPVs were calculated by using the
normal approximation of the binomial distribution. All
analyses were conducted with SAS 9.1 Statistical Software
(SAS Institute Inc., Cary, NC, USA).
Results
Characteristics of the study population
A total of 9,482 patients were identified with the algo-
rithms. Only 2% of the patients consented to have
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medical records were obtained in 83.1% of those who
consented to the study. Demographic characteristics
were similar between respondents and non-respondents.
Among the non-respondents, the mean age was
80.7 years with a standard deviation (SD) of 6.8, and
85.9% were female. Table 2 describes the characteristics
of study subjects identified by each algorithm. Overall,
the mean age was 79.3 (SD 7.1) years, 82.9% were
female, and 98.2% were Caucasians. The patients identi-
fied by the algorithm requiring at least two claims from
a rheumatologist were slightly younger and had more
comorbidities than the patients identified by the other
algorithms.
Positive predictive value for various algorithms
Table 3 presents the PPV of each algorithm. When ‘RA
diagnosis per rheumatologists’ w a su s e da st h eg o l d
standard, the PPVs were 55.7% (95% CI 46.8% to 64.4%)
for the algorithm of at least two claims for RA and
65.5% (95% CI 55.8% to 74.3%) for the algorithm of at
least three claims for RA. When the algorithm was
restricted to at least two claims that were from a rheu-
matologist and that were separated by at least 7 days,
the PPV increased to 66.7% (95% CI 55.5% to 76.6%).
The PPVs of these algorithms were generally lower, ran-
ging from 33.6% to 40.0%, with fulfillment of four or
more of the ACR RA criteria as the gold standard.
When at least one DMARD prescription was required,
the PPV improved to 86.2% (95% CI 74.6% to 93.9%) for
the algorithm of at least two claims for RA, with ‘RA
diagnosis per rheumatologists’ as the gold standard. The
PPV was highest (88.9%, 95% CI 76.0% to 96.3%) for the
algorithm of at least two claims from a rheumatologist
combined with at least one DMARD prescription. When
fulfillment of four or more of the ACR RA criteria was
used as the gold standard, the PPVs of the algorithms
combined with at least one DMARD prescription ranged
from 55.6% to 60.7% (Table 3).
Less than 20% of the patients were identified with
ICD-9 714.9, which is for unspecified inflammatory
polyarthropathy. In a sensitivity analysis, we excluded
those patients and recalculated the PPVs of the algo-
rithms. Overall, the PPV did not improve substantially.
The PPVs were 60.7% (95% CI 51.8% to 69.5%) for the
algorithm of at least two claims for RA and 70.1% (95%
CI 61.0% to 79.2%) for the algorithm of at least three
claims for RA using ‘RA diagnosis per rheumatologists’
as the gold standard. The algorithm of at least two
claims from a rheumatologist had the PPV of 73.0%
(95% CI 62.9% to 83.1%).
Discussion
This study examined the PPV of various algorithms for
identifying patients with RA in health care utilization
data and found that the diagnosis code-based algorithms
had modest PPVs, ranging from 55.7% for the least
restrictive algorithm to 66.7% for the most restrictive,
using the diagnosis of RA by a rheumatologist as the
gold standard. However, we found that requiring a
DMARD prescription improved the PPVs substantially.
Table 1 A list of disease-modifying antirheumatic drugs
included in the study
Abatacept
Adalimumab
Anakinra
Azathioprine
Cyclosporin
D-penicillamine
Etanercept
Gold
Hydroxychloroquine
Infliximab
Leflunomide
Methotrexate
Minocycline
Rituximab
Sulfasalazine
Table 2 Baseline characteristics of study subjects
Algorithms A. At least 2 claims
for RA
B. At least 3 claims
for RA
C. At least 2 claims from a
rheumatologist
a
No claims for
RA
Number 131 110 84 39
Age in years, mean (SD) 79.1 (6.7) 78.8 (6.6) 78.7 (7.0) 80.1 (8.4)
Females, number (percentage) 115 (87.8) 96 (87.3) 73 (86.9) 26 (66.7)
Caucasians, number (percentage) 129 (98.5) 109 (99) 83 (98.8) 38 (97.4)
Comorbidity index, mean (SD) 2.6 (2.3) 2.6 (2.3) 2.7 (2.4) 1.8 (2.5)
Comorbidity index >0, number
(percentage)
109 (83.2) 92 (83.6) 72 (85.7) 20 (51.3)
Rheumatology visits, mean (SD) 1.9 (3.6) 2.2 (3.8) 3.0 (4.1) 0 (0)
DMARD use, number (percentage) 58 (44.3) 56 (50.9) 45 (53.6) 1 (2.6)
aAt least 7 days were required between the claims. DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; SD, standard deviation.
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four or more of the ACR RA criteria was used as the
gold standard.
Previous studies of Medicare claim data for the RA
diagnosis showed the high PPVs over 85% compared
with the chart documentation of RA diagnosis [4,5]. The
better performance of the RA diagnosis codes in these
studies can be explained by a difference in patient popu-
lation as these studies were limited to either a hospital
inpatient setting for joint replacement surgery or rheu-
matology specialty clinics.
Our study has important implications. Based on our
results, a diagnosis code-based algorithm alone is not suf-
ficient to accurately identify patients with RA in the
health care utilization data. Further refinement of the
algorithms with a link to pharmacy claim data for a
DMARD prescription can improve the PPVs of RA diag-
noses in these data. Studies assessing RA-specific compli-
cations or the burden of RA solely on the basis of the
ICD-9 code should be interpreted with caution.
Several limitations of this study should be noted. First,
generalizability can be an issue with the low response
rate, although we did not find a significant difference in
demographic characteristics between respondents and
non-respondents. We attempted to recruit as many
patients as possible and sent multiple recruitment letters
over a period of 3 years, but the response rate was
only 2%. One of the main reasons for this low response
rate is that this study required patients in the community
to provide an authorization to release their medical
records to the study investigators, who were not directly
or indirectly involved in their medical care. Other poten-
tial explanations for such a low response rate include
older age, low socioeconomic status, admission to a nur-
sing home, critical illness, and death. Second, our focus
on the elderly can be seen as a limitation as it is possible
that validity may vary by age group as our study included
only those patients who were 65 or older. However, the
prevalence of RA among adults who are 60 years or older
in the US is approximately 2% [9]; therefore, the elderly
populations contain the substantial proportion of RA
patients in the population. Third, the percentage of the
patients who met the ACR criteria in our review was low.
It might have been underestimated as we did not have
access to all the longitudinal medical records across mul-
tiple physicians. Incompleteness of information that is
needed to assess the fulfillment of the individual ACR RA
criteria in medical records has been previously reported
[10,11]. The diagnostic performance of the ACR classifi-
cation criteria for RA is also known to be problematic in
a clinical setting [12].
Our study demonstrated that the PPVs of RA diagno-
sis codes in the health care utilization data varied con-
siderably across different gold standard definitions.
Table 3 Positive predictive values and 95% confidence intervals of the algorithms to define rheumatoid arthritis in
health care utilization data
Gold standard definition A. At least 2 claims for RA B. At least 3 claims for RA C. At least 2 claims from a rheumatologist
a
DMARD prescription filling is not required
Number 131 110 84
RA per rheumatologists, number 73 72 56
PPV
(95% CI)
55.7
(46.8-64.4)
65.5
(55.8-74.3)
66.7
(55.5-76.6)
At least 4 ACR criteria, number 44 44 33
PPV
(95% CI)
33.6
(25.6-42.4)
40.0
(30.8-49.8)
39.3
(28.8-50.6)
At least 3 ACR criteria, number 56 56 42
PPV
(95% CI)
42.8
(34.2-51.7)
50.9
(41.2-60.6)
50.0
(38.9-61.1)
At least 1 DMARD prescription filling is required
Number 58 56 45
RA per rheumatologists, number 50 49 40
PPV
(95% CI)
86.2
(74.6-93.9)
87.5
(75.9-94.8)
88.9
(76.0-96.3)
At least 4 ACR criteria, number 34 34 25
PPV
(95% CI)
58.6
(44.9-71.4)
60.7
(46.8-73.5)
55.6
(40.0-70.4)
At least 3 ACR criteria, number 42 42 33
PPV
(95% CI)
72.4
(59.1-83.3)
75.0
(61.6-85.6)
73.3
(58.1-85.4)
Positive predictive values (PPVs) are presented as a percentage.
aAt least 7 days were required between the claims. ACR, American College of Rheumatology; CI,
confidence interval; DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis.
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the gold standard, the performance of all three algo-
rithms requiring at least one DMARD prescription was
acceptable, with the PPVs of 86.2% to 88.9%. Even with
fulfillment of three or more of the ACR RA criteria as
the gold standard, the PPVs of our algorithms were
moderate to good (72.4% to 73.3%). Given the limita-
tions of the ACR RA classification criteria for clinical
practice, it may be more appropriate to use ‘RA diagno-
sis per rheumatologists’ as the gold standard.
Conclusions
Our results indicate that, to accurately identify subjects
with RA in health care utilization databases, future
research should consider algorithms that link ICD-9
codes to pharmacy claim data.
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